As the first‐in‐class PARP inhibitor, Olaparib has been approved for the clinical treatment of advanced ovarian cancer, metastatic breast cancer, pancreatic cancer, and prostate cancer. This evidence concerns the gene PARP1 and ovarian carcinoma.